Position in EXEL
as of Jun 30, 2026
· filed Jul 15, 2026
Position Value
$489,962
New position
Shares Held
9,005
first reported quarter
Ownership
0.004%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
#63
of 154 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Harbour Capital Advisors, LLC holds $5,783,688 across 7 Biotechnology names. EXEL ranks #3 (8.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
6,051 | $3,005,713 | |
| 2 | TRVI |
Trevi Therapeutics, Inc.
|
40,200 | $749,730 | |
| 3 | EXEL |
Exelixis, Inc.
This page
|
9,005 | $489,962 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
12,170 | $474,751 | |
| 5 | SNDX |
Syndax Pharmaceuticals Inc
|
20,650 | $451,409 | |
| 6 | KLRA |
Kailera Therapeutics, Inc.
|
16,570 | $365,037 | |
| 7 | RARE |
Ultragenyx Pharmaceutical Inc.
|
7,400 | $247,086 |
All Filings in EXEL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $489,962 | 9,005 | Shares | Sole | 2026-07-15 | |
| No filing history on record for this holder in this stock. | ||||||